Boston Scientific begins trial to evaluate Farapulse Pulsed Field Ablation System for Persistent Atrial Fibrillation
Marlborough: Boston Scientific Corporation has initiated the AVANT GUARD clinical trial to evaluate the safety and effectiveness of the FARAPULSE Pulsed Field Ablation (PFA) System* as a first-line treatment for persistent atrial fibrillation (AF). Outcomes of ablation with the FARAPULSE PFA System – a nonthermal treatment in which electric fields selectively ablate heart tissue – will […]